U.S. National Institutes Of Health Leader Stands Behind Psychedelic Medicines and Cannabis Therapies

WASHINGTON, D.C.–The National Institutes of Health (NIH), is the leading health organization in the U.S.A., Dr. Francis Collins, (who Dr. Anthony Fauci works for) praised the potential of psychedelic research during a U.S. Senate budget hearing last week in Washington D.C.

Collins launded the progress in psilocybin research, which has been tested in clinical trials for depression in the U.S.

“That could be quite exciting, because we all are looking for new approaches to that,” he said, adding that MDMA and LSD are also of interest.

On the topic of cannabis and greater access to the plant for researchers, Collins said “We’re making some progress.”

“What we really need is to moderate the Schedule 1 limitation,” Collins said, adding that he’s discussed the possibility of creating a new category, Schedule I-R, that could create further pathways for research.

(Reporting from The Vancouver Sun and The Growth Op and Other Sources. Image: Getty Images License)